- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00004029
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
I. Assess the toxicity associated with repeated vaccination with recombinant vaccinia virus expressing prostate-specific antigen (rV-PSA) in patients with metastatic adenocarcinoma of the prostate.
II. Determine the optimal dose of rV-PSA given at monthly intervals based on cellular and hormonal immunity.
III. Determine whether vaccination with rV-PSA is associated with anti-tumor activity.
IV. Determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) has an effect on cellular and humoral immunity different from rV-PSA, and whether the addition of GM-CSF has enhanced antitumor effect compared to rV-PSA alone.
OUTLINE: This is an open label, dose escalation study.
Patients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
Patients are followed monthly for 6 months.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically proven adenocarcinoma of the prostate with evidence of metastatic disease based on any of the following:
- Lymph node positive and PSA at least 10 ng/mL
- Bone scan positive and PSA at least 10 ng/mL
- PSA at least 2 ng/mL and rising following radical prostatectomy
- PSA at least 10 ng/mL following radiotherapy
- No symptomatic metastatic disease (bony pain)
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: ECOG 0 or 1
- WBC greater than 2,000/mm3
- Platelet count greater than 100,000/mm3
- Bilirubin less than 2.0 mg/dL
- AST less than 4 times normal
- Creatinine less than 2.0 mg/dL
- Must be type HLA-A2 Prior vaccinia (smallpox) exposure required
- At least normal delayed type hypersensitivity to mumps and Candida
- At least normal CD4:CD8 ratio (greater than 1)
- At least normal lymphocyte proliferation testing (to Con A)
- At least normal immunoglobulin levels
- No evidence of altered immune responsiveness or autoimmune syndromes (e.g., scleroderma, systemic lupus erythematosus)
- No HIV antibody No prior splenectomy
- No known allergy to eggs
- No active extensive skin disorders (e.g, psoriasis, burns, impetigo, disseminated zoster)
- No other serious intercurrent illness
- No active infections unless cleared and at least 3 days since antibiotic therapy
No close contact for 2 weeks after each vaccination with the following people:
- Children less than 3 years old
- Pregnant women
- Individuals with eczema or skin conditions listed above
- Immunosuppressed individuals
PRIOR CONCURRENT THERAPY:
- No concurrent biologic therapy
- No prior chemotherapy for metastatic disease
- No prior hormone therapy for metastatic disease
- Neoadjuvant hormone therapy prior to prostatectomy or radiotherapy allowed
- No concurrent steroids or hormonal medications
- Prior radiotherapy allowed
- Prior surgery allowed
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Arm I
atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity.
Response assessment is performed at eight weeks.
Patients who discontinue therapy prior to eight weeks are considered unevaluable for response.
If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level.
Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle.
Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA) in advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1692, 439, 1999.
- Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant vaccinia virus, PROSTVAC that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1672, 434, 1998.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000065275
- DFCI-96079
- NCI-T95-0086H
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur sargramostim
-
Milton S. Hershey Medical CenterRetiréPneumonie | Le syndrome de détresse respiratoire aiguë | Infection virale respiratoire
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)ComplétéCancer de la prostateÉtats-Unis
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)ComplétéCancer métastatique | Mélanome (Peau)États-Unis
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)ComplétéCancer du rein | Cancer métastatiqueÉtats-Unis, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)Inconnue
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Complété
-
Roswell Park Cancer InstituteComplétéLymphome | Syndromes myélodysplasiques | Leucémie | Troubles myéloprolifératifs chroniques | Maladie du greffon contre l'hôte | Tumeurs myélodysplasiques/myéloproliférativesÉtats-Unis
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)ComplétéCancer métastatique | Mélanome (Peau)États-Unis
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)ComplétéSyndromes myélodysplasiques | Leucémie | Maladies myélodysplasiques/myéloproliférativesÉtats-Unis
-
SanofiRetiré